[Health economics modelling: costs, effectiveness and cost-effectiveness of biological agents in rheumatoid arthritis with particular emphasis on infliximab (REMICADE) therapy]
Majer I, Pentek M, Brodszky V, Gulacsi L
Record ID 32011000024
Hungarian
Details
Project Status:
Completed
Year Published:
2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Hungary
MeSH Terms
- Cost-Benefit Analysis
- Antibodies, Monoclonal
- Antirheumatic Agents
- Arthritis, Rheumatoid
Contact
Organisation Name:
Unit of Health Economics and Technology Assessment in Health Care
Contact Address:
Unit of Health Economics and Technology Assessment in Health Care Department of Public Policy and Management Budapest University of Economic Studies 1125 Budapest Fovam ter 8 Budapest HUNGARY Tel: +36 1 218 8197 Fax: +36 1 218 1466
Contact Name:
laszlo.gulacsi@uni-corvinus.hu
Contact Email:
laszlo.gulacsi@uni-corvinus.hu
Copyright:
Unit of Health Economics and Technology Assessment in Health Care (HunHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.